Thursday, March 5, 2026
12 pm ET
View the recording
New antibody patenting strategies, such as structure-based genus and means plus function claims, are reshaping how antibody genus claims are being written post Amgen v. Sanofi. Join us on Thursday, March 5, 12:00 PM ET, as we discuss examples of antibody genus claims recently allowed by the USPTO based on these strategies.
This webinar will explore:
- New antibody claim strategies that provide a viable path forward for genus claims that align with current USPTO and case-law guidance on enablement and written description
- How comprehensive CDR-Scanning is being used to obtain genus claims based on the common structural feature of the antibody’s paratope (as described in Banik et al., 2025, Nature Biotechnology)
- Examples of antibody genus claim structures recently allowed by the USPTO
